ClinicalTrials.gg
CompletedNCT02607891Updated Dec 20, 2022

A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy

A Phase 2 interventional study of GWP42003-P and Placebo in Epilepsy, sponsored by Jazz Pharmaceuticals. Completed at 5 sites in 3 countries. Open to participants aged 16 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-12-20.

Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
16 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing cannabidiol in Epilepsy — 2 open to participants now, 4 under way, 2 of them phase 3. Cannabidiol · Epilepsy.

Enrollment
10th of 20
35 · median 35
Started
2016
with 3 others
Phase 2
6 of 20
none open now
Registered
10th of 20
by date
Lead sponsor
11 of 20
Jazz Pharmaceuticals

Among the 20 studies testing cannabidiol in Epilepsy, this one is the 10th largest by enrollment, is one of 4 that started in 2016, is one of 6 in phase 2, and was the 10th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

2 of the 20 studies testing cannabidiol in Epilepsy are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing cannabidiol in Epilepsy, or all of them as a file.
02

Study summary

This trial consists of 2 parts: a double-blinded phase and an open-label extension phase. The blinded phase only will be described in this record. Participants will be randomized in a 4:1 ratio to receive GWP42003-P or matching placebo. The hypothesis is that levels of stiripentol (STP) or valproate (VPA) may be altered (increased or decreased) as a result of using GWP42003-P.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Cannabidiol
  • GWP42003-P
  • Epidiolex
  • Stiripentol
  • Valproate
04

Who can participate

Ages eligible
16 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Note: Participants who enroll in Sweden must be aged 18-55 years.

Key Inclusion Criteria:

  • Participant must be taking STP (for the STP arm) or VPA (for the VPA arm) and no more than 2 other antiepileptic drugs (AEDs) during the blinded period of the trial.

    • In the VPA arm only, the participant must not be receiving STP (VPA allowed in STP arm).
  • AED doses, including STP or VPA, must be stable for 4 weeks prior to screening and regimen must remain stable throughout the duration of the blinded period of the trial.
  • Participant must have a documented magnetic resonance imaging/computerized tomography of the brain that ruled out a progressive neurologic condition.
  • Participant must have experienced at least 1 countable uncontrolled seizure of any type (i.e., tonic-clonic, tonic, clonic, atonic, partial onset or focal: focal seizures with retained consciousness and a motor component, focal seizures with impaired consciousness, focal seizures evolving to bilateral secondary generalization) within 2 months prior to randomization.
  • Intervention with vagus nerve stimulation and/or ketogenic diet must be stable for 4 weeks prior to baseline and the participant must be willing to maintain a stable regimen during the blinded period of the trial.
  • Participant must abstain from alcohol during the blinded period of the trial.

Key Exclusion Criteria:

  • Participant has unstable medical conditions other than epilepsy.
  • Participant has a history of symptoms related to a drop in blood pressure due to postural changes (e.g., dizziness, light-headedness, blurred vision, palpitations, weakness, syncope).
  • Participant has a , corrected for heart rate with Bazett's formula (QTcB), greater than:

    • 450 msec for males.
    • 470 msec for females.
    • 480 msec if right bundle branch block is present.
  • Participant has any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the C-SSRS in the last month or at screening.
  • Participant has had clinically relevant symptoms or a clinically significant illness in the 4 weeks prior to screening or enrollment, other than epilepsy.
  • Participant is currently using felbamate and has been taking it for less than 12 months prior to screening.
  • Participant has consumed alcohol during the 7 days prior to enrollment and is unwilling to abstain during the blinded phase of the trail.
  • Participant is currently using or has in the past used recreational or medicinal cannabis, or synthetic cannabinoid-based medications (including Sativex®) within the 3 months prior to trial entry.
  • Participant has any known or suspected history of any drug abuse or addiction.
  • Participant is unwilling to abstain from recreational or medicinal cannabis, or synthetic cannabinoid based medications (including Sativex) for the duration for the study.
  • Participant has consumed grapefruit or grapefruit juice 7 days prior to enrollment and is unwilling to abstain from drinking grapefruit juice within 7 days of pharmacokinetic visits.
  • Participant has any known or suspected to cannabinoids or any of the of the Medicinal Product (IMP), e.g., sesame oil.
  • Participant has received an IMP within the 12 weeks prior to the screening visit.
  • Participant has significantly impaired hepatic function at the screening or randomization visit, defined as any of the following:

    • (ALT) or aspartate aminotransferase (AST) > 5 × (ULN).
    • ALT or AST > 3 × ULN and total (TBL) > 2 × ULN or (INR) > 1.5.
    • ALT or AST > 3 × ULN with the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (> 5%).
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    STP + GWP42003-P

    Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the open-label-extension (OLE) phase or who withdraw early. STP Arm: Last patient completion October 2018

    Drug: GWP42003-P

  • Placebo comparator
    STP + Placebo

    Administered orally, twice daily (morning and evening; immediately after the participant's STP dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early. STP Arm: Last patient completion February 2018

    Drug: Placebo

  • Experimental
    VPA + GWP42003-P

    Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of 100 mg/mL GWP42003-P to a maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early. VPA Arm: Last patient completion February 2018

    Drug: GWP42003-P

  • Placebo comparator
    VPA + Placebo

    Administered orally, twice daily (morning and evening; immediately after the participant's VPA dose), commencing with up-titration of placebo to an equivalent maintenance dose of 20 mg/kg/day over 11 days. Participants remain on the maintenance dose for a further 14 days. Dosing is tapered (10% each day) for participants who do not enter the OLE phase or who withdraw early. VPA Arm: Last patient completion January 2018

    Drug: Placebo

Interventions

  • Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

    Also known as: Cannabidiol, CBD, Epidiolex

  • DrugPlacebo

    Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD).

    The Cmax of STP, VPA and CBD is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

  2. Time to the maximum plasma concentration (Tmax) of STP, VPA and CBD.

    The Tmax of STP, VPA and CBD is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

  3. Area under the curve (AUC) from zero to final time of positive detection (0-t) of STP, VPA and CBD.

    The AUC(0-t) of STP, VPA and CBD is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

  4. Area under the plasma concentration time curve over a dosing interval, where tau is the dosing interval [AUCtau].

    The AUC(tau) of STP, VPA, and CBD is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

Secondary outcomes

  1. Number of participants who experienced an adverse event.

    The number of participants who experienced an adverse event during the trial is presented.

    Time frame: Up to 11 weeks.

  2. Number of participants with a clinically significant change in 12-lead electrocardiogram (ECG).

    The number of participants with a clinically significant change in ECG is presented.

    Time frame: Up to 7 weeks.

  3. Number of participants with a clinically significant change in serum biochemistry.

    The number of participants with a clinically significant change in serum biochemistry is presented.

    Time frame: Up to 7 weeks.

  4. Number of participants with a clinically significant change in hematology.

    The number of participants with a clinically significant change in hematology is presented.

    Time frame: Up to 7 weeks.

  5. Number of participants with a clinically significant change in urinalysis.

    The number of participants with a clinically significant change in urinalysis is presented.

    Time frame: Up to 7 weeks.

  6. Number of participants with a clinically significant change in vital signs.

    The number of participants with a clinically significant change in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate) is presented.

    Time frame: Up to 7 weeks.

  7. Number of participants with a clinically significant change in physical examination.

    The number of participants with a clinically significant change in physical examination is presented.

    Time frame: Up to 7 weeks.

  8. Number of participants with a treatment-emergent suicidality flag.

    Suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS). The number of participants with a treatment-emergent flag is presented.

    Time frame: Up to 7 weeks.

  9. Seizure frequency by subtype.

    The frequency of each subtype of seizure at baseline and end of treatment is presented.

    Time frame: Up to 6 weeks.

  10. Number of participants with a treatment-emergent finding indicative of drug abuse liability.

    Abuse liability was assessed through monitoring of triggering adverse events of interest and study medication accountability discrepancies. Any findings were assigned to an appropriate classification by the investigator. The number of participants with a treatment-emergent finding indicative of drug abuse liability is presented.

    Time frame: Up to 7 weeks.

  11. Cmax of 4-ene-VPA, clobazam (CLB), N-desmethylclobazam (N-CLB), levetiracetam (LEV), and topiramate (TOP).

    The Cmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

  12. Tmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.

    The Tmax of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

  13. AUC(0-t) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.

    The AUC(0-t) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

  14. AUC(tau) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP.

    The AUC(tau) of 4-ene-VPA, CLB, N-CLB, LEV, and TOP is presented.

    Time frame: 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, and 12 hours post-dose.

07

Study locations

5 sites
  • SEIN - Epilepsy Institute in the Netherlands Foundation
    Zwolle, Netherlands
  • Hospital Universitari Vall d'Hebron
    Barcelona, Spain
  • Hospital Ruber Internacional
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Sevilla, Spain
  • Sahlgrenska University Hospital
    Göteborg, Sweden
08

References and documents

Publications

  • Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M. A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug-Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy. CNS Drugs. 2020 Jun;34(6):661-672. doi: 10.1007/s40263-020-00726-4. PubMed 32350749 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Sep 2018, 22 months.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 22 months is close to that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2015
First posted
Nov 18, 2015
StartActual
Nov 9, 2016
Primary completionActual
Sep 11, 2018
CompletionActual
Oct 2, 2018
Last update
Dec 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02607891
Responsible party
Sponsor
First posted
Nov 18, 2015
Start date
Nov 9, 2016
Primary completion
Sep 11, 2018
Completion
Oct 2, 2018
Last update
Dec 20, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion